What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Stephen H. Caldwell mainly investigates Internal medicine, Cirrhosis, Gastroenterology, Fatty liver and Liver disease.
His work carried out in the field of Cirrhosis brings together such families of science as Hyperinsulinemia, Hepatitis, Biopsy, Vascular disease and Fibrosis.
His Fibrosis research incorporates elements of Steatosis and Insulin resistance.
His studies deal with areas such as Hepatitis B, Immunology, Liver transplantation, Transplantation and Hepatitis B virus as well as Gastroenterology.
As a part of the same scientific family, Stephen H. Caldwell mostly works in the field of Fatty liver, focusing on Diabetes mellitus and, on occasion, Bioinformatics.
Stephen H. Caldwell interconnects Epidemiology, Surgery and Intensive care medicine in the investigation of issues within Liver disease.
His most cited work include:
- Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference (1828 citations)
- Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference (1828 citations)
- Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. (924 citations)
What are the main themes of his work throughout his whole career to date?
Stephen H. Caldwell mostly deals with Internal medicine, Gastroenterology, Cirrhosis, Surgery and Liver disease.
His research in the fields of Fatty liver, Steatohepatitis and Liver transplantation overlaps with other disciplines such as In patient.
His Fatty liver research is multidisciplinary, incorporating elements of Steatosis and Metabolic syndrome.
His Gastroenterology research is multidisciplinary, incorporating perspectives in Nonalcoholic steatohepatitis, Nonalcoholic fatty liver disease, Hepatitis C, Hepatocellular carcinoma and Fibrosis.
His Cirrhosis study incorporates themes from Diabetes mellitus, Thrombosis and Coagulopathy.
His study looks at the relationship between Liver disease and topics such as Intensive care medicine, which overlap with Prothrombin time.
He most often published in these fields:
- Internal medicine (55.40%)
- Gastroenterology (38.64%)
- Cirrhosis (30.40%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (55.40%)
- Gastroenterology (38.64%)
- Cirrhosis (30.40%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Gastroenterology, Cirrhosis, Liver disease and In patient.
Stephen H. Caldwell works on Gastroenterology which deals in particular with Steatosis.
His Cirrhosis study combines topics from a wide range of disciplines, such as Hepatocellular carcinoma, Liver transplantation, Surgery and Intensive care medicine.
The concepts of his Liver disease study are interwoven with issues in Hemostasis, Severity of illness, Cohort and Bioinformatics.
His studies in Fibrosis integrate themes in fields like Confidence interval and Hazard ratio.
The subject of his Fatty liver research is within the realm of Disease.
Between 2015 and 2021, his most popular works were:
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial (267 citations)
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (172 citations)
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (154 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
His primary scientific interests are in Cirrhosis, Internal medicine, Gastroenterology, Steatohepatitis and Intensive care medicine.
His Cirrhosis research is multidisciplinary, relying on both Thrombosis, Surgery and Liver transplantation.
His is involved in several facets of Internal medicine study, as is seen by his studies on Fibrosis, Hepatology, Nonalcoholic fatty liver disease, Liver disease and Cohort.
His Gastroenterology research includes elements of Placebo, Biopsy, Liver biopsy and Hazard ratio.
His Steatohepatitis study deals with the bigger picture of Fatty liver.
His Fatty liver research integrates issues from Liraglutide, Bioinformatics, Statin, Metabolic syndrome and Pioglitazone.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
